-
Featured
Biomarkers of T Cell Exhaustion in Checkpoint Inhibitor Therapy
Could altering the balance between two CD8+ T cell states enhance immunotherapies? Research from the Massachusetts General Hospital Cancer Center seeks to find the answer.
-
Featured
New Approach to CAR T-Cell Therapy for Glioblastoma Aims to Circumvent Antigen Escape
A dual-antigen approach to immunotherapy for glioblastoma, pioneered at Massachusetts General Hospital, addresses antigenic heterogeneity and may have applications for treating other types of solid tumors.
-
Featured
Using Immunotherapy to Treat Brain Tumors
In this video, William Curry, MD, discusses advancements in immunotherapy to target brain tumors. In clinical trials, he has seen the safety and strong immune activity of vaccinating patients with their own tumor cells, which has made him optimistic about the future of treatment for patients with brain tumors.
Immuno-Oncology contributors
-
-
Chin-Lee Wu, MD, PhD
Associate Pathologist, Massachusetts General Hospital and Mass General Cancer Center, Associate Professor of Pathology, Harvard Medical School, Director, Genitourinary Pathology Services
Recent Article
Computational Fluid Dynamics to Assess Urine Flow After Surgery for Benign Prostatic Hyperplasia
-
Joseph H. Schwab, MD
Chief, Orthopaedic Spine Surgery, Director, Spine Oncology & Co-Director, Stephen L. Harris Chordoma Center, Associate Professor of Orthopedic Surgery, Harvard Medical School
Recent Article
Novel Technique Reconstructs Lumbar Spine After Spondylectomy of Malignant Tumor
-
Kerry L. Reynolds, MD
Clinical Director, Inpatient Oncology Units, Director, Severe Immunotherapy Complications Program
Recent Article
Researchers Chart the Course of Severe Checkpoint Inhibitor-related Colitis -
Michael L. Dougan, MD, PhD
Physician, Division of Gastroenterology, Massachusetts General Hospital, Director, GI Center for Cancer Complications, Mass General Cancer Center, Assistant Professor of Medicine, Harvard Medical School
Recent Article
Update on the Use of Human Antibody Bamlanivimab to Treat COVID-19: Q&A with Michael Dougan, MD, PhD
-
Nir Hacohen, PhD
Director, MGH Center for Cancer Immunology
Center for Cancer Research , Professor of Medicine, Harvard Medical School, Senior Member, Broad InstituteRecent Article
MGH Research Scholars Respond to COVID-19
-
Tomas G. Neilan, MD, MPH
Director, Cardio-Oncology Program, Massachusetts General Hospital, Co-Director, Cardiac MR PET CT Program
Recent Article
Immune Checkpoint Inhibitor Therapy Increases Risk of Atherosclerotic Cardiovascular Events
-
Whitfield B. Growdon, MD
Center for Gynecologic Oncology
Recent Article
Understanding the Molecular Underpinnings of Gynecologic Cancers
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology
Recent Article
Case Reports: Mapping of the Thalamocortical Tract in Asleep Craniotomies
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
